African Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trials

CEPI backs Minapharm's Bundibugyo ebolavirus vaccine candidate, based on ProBioGen's proprietary MVA-CR19 platform OSLO, Norway, CAIRO and BERLIN, Aug. 27, 2026 /PRNewswire/ -- Leading African biopharmaceutical company Minapharm Group, headquartered in Egypt with subsidiaries in Berlin,...